GRM1 encodes a G-protein coupled receptor for glutamate that activates phosphatidylinositol-calcium second messenger signaling in the central nervous system 1. The receptor mediates synaptic plasticity processes, including long-term potentiation in the hippocampus and long-term depression in the cerebellum, and may function in retinal light responses. GRM1 signaling is regulated by Homer, a dendritic protein that binds the receptor's carboxy terminus and is dynamically responsive to synaptic activity 2. Two splice variants of human GRM1 exist with comparable pharmacological properties to rat orthologs 3. Beyond neurotransmission, GRM1 has emerged as an oncogenic driver in benign and malignant melanocytic tumors. GRM1 gene fusions (including MYO10::GRM1 and ZEB2::GRM1) occur in blue nevi and blue melanomas lacking canonical GNAQ/GNA11 mutations, with GRM1 consistently overexpressed in fusion-positive cases 4. Similarly, GRM1 rearrangements and massive upregulation (>100-fold) characterize chondromyxoid fibroma, a benign bone tumor, where promoter-swapping events drive tumorigenesis in approximately 90% of cases 5. A genetic association study identified a GRM1 intronic polymorphism (rs362962) associated with increased melanoma susceptibility in patients with low sun exposure and truncal/extremity tumors 6. GRM1 has also been implicated as one of multiple candidate genes in attention-deficit/hyperactivity disorder pathogenesis 7. Immunotherapy studies using transgenic melanoma models demonstrate that restoring dendritic cell function enhances checkpoint blockade efficacy, suggesting potential immunotherapeutic approaches in GRM1-driven tumors.